Peptide for Treatment and Early Diagnosis of Alzheimer's Disease and Other Tauopathies

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes new peptides that are specifically designed to bind to aggregated tau proteins, which are closely associated with Alzheimer’s disease and other tauopathies. These peptides can inhibit the formation of toxic tau aggregates, convert existing harmful aggregates into non-toxic forms, and can also be used as diagnostic probes for early detection of diseases involving tau aggregation, such as Alzheimer’s disease, by enabling visualization with imaging techniques.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of Alzheimer's disease by preventing or detoxifying tau protein aggregates in the brain
• Treatment of other tauopathies, such as frontotemporal dementia and certain forms of Parkinson’s disease
• Early diagnosis of Alzheimer's and related tauopathies using labeled peptides for in vivo imaging (e.g., PET, MRI, SPECT) to detect pathological tau aggregates
• Development of pharmaceutical compositions, drugs, vaccines, or supplements containing the peptides for disease management or prevention
• Use of peptide-based kits for laboratory or clinical analysis of tau protein in biological samples

BenefitsContent extracted from patent full text and abstract with AI.

• Addresses both treatment and early diagnostic needs for Alzheimer’s and related disorders
• Directly targets aggregated tau, which correlates better with disease progression than amyloid plaques, providing potentially more effective therapies and diagnostics
• Peptides can convert toxic tau aggregates to non-toxic forms, potentially stopping disease progression
• D-peptide forms offer reduced immunogenicity and longer stability in biological systems
• Labeled peptides enable the possibility of non-invasive early diagnosis via brain imaging, which is critical for timely intervention
• Versatile applications: peptides can be used in therapeutics, diagnostics, and research
• Potential for combination therapies by coupling with other drugs, anti-inflammatories, or other active substances

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to novel tau protein aggregation-binding peptides, homologs, fragments, parts and polymers thereof as well as to the use thereof.